tailieunhanh - Systemic and tumor-directed therapy for oligometastatic prostate cancer: Study protocol for a phase II trial for veterans with de novo oligometastatic disease

The treatment paradigm for metastatic hormone-sensitive prostate cancer (mHSPC) patients is evolving. PET/CT now offers improved sensitivity and accuracy in staging. | Systemic and tumor-directed therapy for oligometastatic prostate cancer Study protocol for a phase II trial for veterans with de novo oligometastatic disease

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN